RLRichard R. Love

Richard R. Love

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Richard R. Love has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Thomas C. Havighurst

    Biostatistics and Medical Informatics, and

    7 shared publications
  • Nguyen Ba Duc

    Hospital K, National Cancer Institute

    6 shared publications
  • D. Craig Allred

    From the Departments of Medicine and Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI; Hospital K, Hanoi, Vietnam; People’s Hospital of Haimen City, Haimen, Jiangsu, China; and Department of Pathology, Baylor College of Medicine, Houston, TX

    3 shared publications
  • David L. DeMets

    From the Departments of Medicine and Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI; Hospital K, Hanoi, Vietnam; People’s Hospital of Haimen City, Haimen, Jiangsu, China; and Department of Pathology, Baylor College of Medicine, Houston, TX

    3 shared publications
  • Nguyen Van Dinh

    Department of Breast Surgery, National Cancer Hospital, Hanoi, Vietnam

    3 shared publications
  • Tian-Zhen Shen

    People’s Hospital of Haimen City, Haimen, Jiangsu, China

    3 shared publications

Latest Publications

  • Endocrine Effects of Tamoxifen Plus Exemestane in Postmenopausal Women with Breast Cancer

    by Richard R. Love, Paul R. Hutson, Thomas C. Havighurst, James F. Cleary

    Purpose: In some specific circumstances, combined hormonal therapies for breast cancer seem to be more effective than single maneuvers. In two laboratory mammary cancer models, the combination of the aromatase inactivator exemestane plus tamoxifen gives a higher response rate than is found with either agent alone.


  • Models of Breast Cancer Growth and Investigations of Adjuvant Surgical Oophorectomy

    by Richard R. Love, John E. Niederhuber

    Clinical observations of the natural history of breast cancer and its response to a variety of therapeutic interventions have contributed to changing concepts about the growth and metastatic spread of this disease. Increased attention has been given to tumor cell dormancy and the occurrence of greatly delayed metastatic disease development, which has been important to rethinking therapy. Although gene profiling of breast tumors recently has highlighted the importance of individual tumor characteristics in patients' prognosis, considerable data also support the concept of breast cancer as a problem of macro- and microenvironmental regulatory imbalance and dynamic chaos. Observations of unexpectedly large survival benefits from adjuvant surgical oophorectomy done in the luteal phase of the menstrual cycle in premenopausal women are consistent with an interpretation that extratumoral interactions in the host environment are important in prognosis. These observations also suggest that a treatment paradigm shift from an exclusive focus on cell kill and specific tumor cell molecular targets to one focused also on broad host regulatory control may be useful. Clinical trials and laboratory mechanistic investigations based on these data and observations can determine the potential impact of therapeutic interventions targeting host system macro and micro tumor cell environments.


  • Horse chestnut seed extract for the treatment of arm lymphedema

    by P. R. Hutson, R. R. Love, J. F. Cleary, S. A. Anderson, L. Vanummersen, S. L. Morgan-Meadows, E. A. Doran

    8095 Background: Lymphedema of the arm occurs frequently as a consequence of surgical and radiation damage to the major lymphatics during lymph node dissection (LND) and adjuvant treatment of breast cancer. Usual lymphedema treatments are massage, compression sleeves and wraps; there are no drug treatments currently available in the USA. This is an interim report of our use of Horse chestnut seed extract (HCSE) for the treatment of arm lymphedema in breast cancer survivors. HCSE is widely used in Europe for venous and lymphatic disorders, and is postulated to act by decreasing capillary and interstitial permeability. Methods: In this double-blind, randomized, and placebo-controlled study, eligible subjects with stable arm lymphedema receive placebo or HCSE (50mg escins) twice daily PO for three months, followed by a 1 month washout. Eligible subjects have affected : unaffected arm edema ratios of ≥ 1.1 to 1 by bioelectric impedance, and significant response was empirically set as a 15% decrease in arm ratios. Arm edema is measured concurrently with serial tape measurements, water displacement, and bioelectric impedance. Subjective assessments include the FACT-B QOL instrument and a 16-item experimental lymphedema questionnaire. Results: 25 subjects (of 68 sought) are evaluable at 3 months. 24 patients are at intermediate assessment points and accrual continues. One patient developed progression of known breast cancer metastases; one developed minor, reversible dizziness and tolerated 50% dose reduction. There are no statistically significant differences in the amount of lymphedema at 3 months by any of the measurement techniques. Small changes in arm volume are not reflected by correlative changes in the scores of the QOL instruments. Conclusions: HCSE at doses commonly used for treating CVI or varicose veins is well tolerated in breast cancer survivors with lymphedema. This interim analysis does not demonstrate significant objective or subjective benefit of HCSE in reducing arm lymphedema. QOL questionnaires need improvement to identify issues that more specifically reflect the impact of lymphedema. Funded by the Susan G. Komen Breast Cancer Research Foundation (BCTR 0100506). No significant financial relationships to disclose.


  • Duration of Signs and Survival in Premenopausal Women with Breast Cancer

    by Richard R. Love, Nguyen Ba Duc, Linda C. Baumann, Pham Thi Hoang Anh, Ta Van To, Zheng Qian, Thomas C. Havighurst

    Condensed. Among 550 women reporting a lump as the first sign of breast cancer, those with this sign for 6–29 months compared to those with 1–6 months, had bigger tumors and more frequent axillary...


  • Open Access

    Cancer Prevention Services and Physician Consensus in Primary Care Group Practices

    by Richard R. Love, Linda C. Baumann, Roger L. Brown, Susan A. Fontana, Caroline C. Clark, Louis A. Sanner, James E. Davis

    Background: We conducted a randomized clinical trial of interventions to achieve physician consensus, practice changes, and patient activation designed to help primary care group practices enhance the delivery of cancer prevention and screening services. Methods: In each of 42 primary care practices in 1991 to 1994, we studied approximately 60 patients per physician who were between the ages 53 and 64. Data sources included patient and physician questionnaires, medical record audits of consenting patients for evidence of 11 cancer prevention services during the previous 3 years, and telephone interviews with key practice personnel. Results: None of the interventions was associated with significant changes in frequency of services or procedures received or provided. Increased frequencies of services overall and of specific activities were associated with HMO membership or insurance coverage for six screening procedures. Patient reports of clinic staff recommendations to have each of six screening procedures were specifically associated with higher frequencies of services (P = 0.001). Conclusions: Demonstration of intervention impact may have been limited because the rates of prevention services were significantly higher in this study than have been reported elsewhere. These results might be explained by selection biases inherent in studying patients with a regular provider, overall practice trends for changes in provision of the studied services, and the study methods.


  • Breast Cancer from a Public Health Perspective

    by Richard R. Love, Susan M. Love, Adriano V. Laudico

    By 2010, the majority of approximately 1.5 million annual new cases of breast cancer will be diagnosed in women in countries with limited resources. Public health approaches to medical problems emphasize the importance of practical, limited toxicity and very inexpensive interventions. While clinical trials in Western countries are testing the concept of breast cancer prevention, they are not defining useful public health approaches. Early detection of breast cancer using mammography, while effective, is a high‐technology, expensive approach. Adjuvant systemic and radiation therapies are increasingly expensive; careful consideration of efficacy and cost‐efficacy data appear warranted. Public health perspectives thus suggest that many current “standard” approaches to breast cancer in Western countries cannot help the majority of women in the world.


  • Postmastectomy radiotherapy in premenopausal Vietnamese and Chinese women with breast cancer treated in an adjuvant hormonal therapy study

    by Richard R Love, Nguyen Ba Duc, Nguyen Cong Binh, Peter A Mahler, Bruce R Thomadsen, Nguyen Hong Long, Tian-Zhen Shen, Thomas C Havighurst


  • Ornithine Decarboxylase (ODC) as a Prognostic Factor in Operable Breast Cancer

    by Richard R. Love, Stephanie H. Astrow, Alan M. Cheeks, Thomas C. Havighurst

    Increased ornithine decarboxylase (ODC) activity, measured biochemically in breast cancers, has been associated with increased risk for recurrence of disease and death. Recently an...


  • HER-2/neu Overexpression and Response to Oophorectomy Plus Tamoxifen Adjuvant Therapy in Estrogen Receptor-Positive Premenopausal Women With Operable Breast Cancer

    by Richard R. Love, Nguyen Ba Duc, Thomas C. Havighurst, Syed K. Mohsin, Qian Zhang, David L. DeMets, D. Craig Allred

    Purpose: Studies evaluating the relationship of HER-2/neu breast tumor status and response to adjuvant endocrine therapy have reached conflicting conclusions about resistance of HER-2/neu-positive tumors to this treatment. We studied 282 patients participating in a randomized controlled trial of adjuvant oophorectomy and tamoxifen or observation who had estrogen receptor-positive tumors and whose tumors were evaluated for HER-2/neu overexpression by immunohistochemistry. Patients and Methods: Univariate and multivariate Cox proportional hazards regression models and Kaplan-Meier disease-free and overall survival estimate methods were used. Results: HER-2/neu overexpression was a negative prognostic factor for overall survival. In univariate analyses, in HER-2/neu-positive patients, the hazard ratio (HR) for disease-free survival (DFS) with adjuvant endocrine therapy was 0.37 (95% confidence interval [CI], 0.26 to 0.89); for HER-2/neu-negative patients, the corresponding HR for DFS was 0.48 (95% CI, 0.31 to 0.71). The overall survival (OS) data were HR=0.26 (95% CI, 0.07 to 0.92) and HR=0.68 (95% CI, 0.32 to 1.42) for HER-2/neu-positive and HER-2/neu-negative patients, respectively. In multivariate models, the P values for tests of interaction of HER-2/neu status and response to adjuvant endocrine therapy were 0.18 and 0.07 for DFS and OS, respectively. Kaplan-Meier DFS and OS curves and 3-year DFS estimates were consistent in showing greater benefit to the HER-2/neu-positive subgroup given adjuvant treatment. Conclusion: HER-2/neu overexpression does not adversely and may favorably influence response to adjuvant oophorectomy and tamoxifen treatment in patients with estrogen receptor–positive tumors.